EXAGEN INC. (XGN): Submission of Matters to a Vote of Security Holders

EXAGEN INC. (XGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. exdx-20260609 0001274737 FALSE 0001274737 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Original reporting
Published Jun 9, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$XGN
Neutral
high confidence
Mentioned
$XGN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$XGNNeutralLow
01

Why it matters

Confirms the election of two Class I directors, ratification of BDO USA as independent auditor for 2026, and an advisory approval of executive compensation.

02

Market read

Traders may treat this as a confirmation/housekeeping disclosure; it typically does not change valuation drivers absent a surprise outcome.

03

What to watch

The filing does not disclose whether any proposal faced meaningful opposition beyond a few votes against/withheld; without context from the proxy, market interpretation may be limited.

Relevance 6/10Novelty 2/10Timing: after-hours / filed June 9, 2026

Background

Item 5.07 of Form 8-K reports final results of stockholder votes from the company’s annual meeting.

Company-level read

Ticker impact

$XGNNeutralHigh confidence
Context

Exagen filed an 8-K confirming final vote results from its June 9, 2026 annual meeting, including director elections and auditor ratification.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless votes imply governance/audit changes beyond expectations.

Evidence & confidence

The filing is a standard post-meeting tabulation (Item 5.07) with no new financial guidance, deal, litigation, or operational change described.

Market effects

Minimal; governance vote outcomes do not reset sector expectations.

Minimal; US-listed microcap governance filing.

Minimal; no cross-border transaction or regulatory action mentioned.

Counterpoint

If investors were uncertain about auditor continuity or board composition, the final vote totals could reduce uncertainty and modestly support sentiment.

Key entities

  • Exagen Inc.

    Nasdaq-listed issuer filing the 8-K with final annual meeting vote results.

  • BDO USA, P.C.

    Independent registered public accounting firm ratified for the fiscal year ending Dec. 31, 2026.

  • Tina S. Nova, Ph.D.

    Elected Class I director for a three-year term (final vote totals reported).

  • Scott Kahn, Ph.D.

    Elected Class I director for a three-year term (final vote totals reported).

Related articles

$XGNLow

Exagen Inc. Reports Third Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Third Quarter 2026 Financial Results Third Quarter Revenue Grew 7% to $18.4 Million Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30% November 10, 2026 Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a precisio

$XGNMedAI 8/10

Exagen Reports Record Second-Quarter 2026 Revenue and Raises Full-Year Guidance

Exagen (NASDAQ:XGN) reported record Q2 2026 revenue of $19.9 million, up 16% year over year, driven by an 11% rise in AVISE CTD testing volume and a 4% higher trailing twelve-month average selling price to $446 per test. Adjusted EBITDA loss narrowed to $0.1 million. Exagen raised full-year 2026 revenue guidance to $72 million-$75 million from $70 million-$73 million.

$XGNMedAI 8/10

Exagen Inc. Q2 2026 Earnings Call Summary

Exagen Inc. reported record Q2 2026 revenue of $19.9 million, up 16% year over year, helped by record AVISE test volumes and higher trailing 12-month ASP near $446. The company raised full-year 2026 revenue guidance to $72 million to $75 million and expects adjusted EBITDA breakeven around $80 million of revenue. Exagen also discussed collections, reimbursement timing, and a myositis product launch in early 2027.

$XGNMed

Exagen Inc. Reports Second Quarter 2026 Financial Results

EXAGEN INC. (XGN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exagen Inc. Reports Second Quarter 2026 Financial Results Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million August 4,

$VMed

Visa adds Monad as stablecoin settlement run rate tops $25B

Visa has added Monad to its stablecoin settlement program, which now processes over $25B annually. Monad confirmed the integration, allowing issuers and acquirers to settle Visa obligations using stablecoins. Visa's CEO reported a tenfold increase in settlement volume from a year earlier. The program supports 10 blockchains and 225 stablecoin-linked card programs across 50+ countries.